Synonyms: RA-101495 | RA101495 | Zilbrysq®
zilucoplan is an approved drug (FDA & EMA (2023))
Compound class:
Peptide
Comment: Zilucoplan (RA101495) is a synthetic, macrocyclic peptide that blocks the cleavage of complement C5 into C5a and C5b which occurs as a consequence of activation of the classical, alternative, or lectin pathways. This mechanism of action inhibits formation of the membrane attack complex (MAC). It was developed by RaPharma for the treatment of tissue-based complement-mediated disorders.
|
|
Classification ![]() |
|
Compound class | Peptide |
Approved drug? | Yes (FDA & EMA (2023)) |
Approved drug? | Yes. FDA (2023) | EMA (2023) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10602 | zilucoplan |
Synonyms ![]() |
RA-101495 | RA101495 | Zilbrysq® |
Database Links ![]() |
|
CAS Registry No. | 1841136-73-9 (source: WHO INN record) |
GtoPdb PubChem SID | 387271627 |
PubChem CID | 133083018 |
Search Google for chemical match using the InChIKey | JDXCOXKBIGBZSK-PSNKNOTQSA-N |
Search Google for chemicals with the same backbone | JDXCOXKBIGBZSK |
Search PubMed clinical trials | zilucoplan |
Search PubMed titles | zilucoplan |
Search PubMed titles/abstracts | zilucoplan |
UniChem Compound Search for chemical match using the InChIKey | JDXCOXKBIGBZSK-PSNKNOTQSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | JDXCOXKBIGBZSK-PSNKNOTQSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Zilucoplan (links to external site)
Cat. No. HY-P3502 |